The Cooper Companies, Inc. (NASDAQ:COO) Shares Purchased by Xponance Inc.

Xponance Inc. lifted its position in The Cooper Companies, Inc. (NASDAQ:COO) by 5.4% in the fourth quarter, HoldingsChannel reports. The firm owned 32,098 shares of the medical device company’s stock after buying an additional 1,656 shares during the period. Xponance Inc.’s holdings in Cooper Companies were worth $2,951,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Empowered Funds LLC raised its position in Cooper Companies by 8.7% in the third quarter. Empowered Funds LLC now owns 3,086 shares of the medical device company’s stock valued at $341,000 after purchasing an additional 248 shares during the period. Thrivent Financial for Lutherans raised its holdings in Cooper Companies by 26.9% in the 3rd quarter. Thrivent Financial for Lutherans now owns 72,001 shares of the medical device company’s stock valued at $7,945,000 after buying an additional 15,258 shares during the period. Pathstone Holdings LLC lifted its position in Cooper Companies by 3.8% in the third quarter. Pathstone Holdings LLC now owns 22,109 shares of the medical device company’s stock valued at $2,440,000 after buying an additional 800 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG purchased a new position in Cooper Companies during the third quarter worth about $1,154,000. Finally, Advisors Asset Management Inc. increased its position in shares of Cooper Companies by 24.6% during the third quarter. Advisors Asset Management Inc. now owns 34,639 shares of the medical device company’s stock valued at $3,822,000 after acquiring an additional 6,839 shares during the last quarter. 24.39% of the stock is currently owned by institutional investors and hedge funds.

Cooper Companies Trading Up 1.6 %

NASDAQ:COO opened at $81.71 on Friday. The Cooper Companies, Inc. has a 1 year low of $77.05 and a 1 year high of $112.38. The stock has a market cap of $16.34 billion, a P/E ratio of 41.90, a P/E/G ratio of 2.25 and a beta of 1.02. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.12 and a current ratio of 1.91. The stock has a 50-day simple moving average of $90.05 and a 200-day simple moving average of $98.14.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings results on Thursday, March 6th. The medical device company reported $0.92 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.92. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The firm had revenue of $964.70 million during the quarter, compared to the consensus estimate of $981.25 million. As a group, analysts anticipate that The Cooper Companies, Inc. will post 3.98 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on COO. Morgan Stanley lowered their price objective on shares of Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating for the company in a research report on Friday, December 6th. StockNews.com cut Cooper Companies from a “buy” rating to a “hold” rating in a research note on Wednesday, December 11th. Piper Sandler reissued an “overweight” rating and set a $115.00 target price (down previously from $120.00) on shares of Cooper Companies in a research note on Friday, March 7th. Citigroup lowered their target price on Cooper Companies from $115.00 to $110.00 and set a “buy” rating for the company in a report on Friday, March 7th. Finally, BNP Paribas raised shares of Cooper Companies to a “hold” rating in a research note on Thursday, March 13th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $110.25.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.